Trial Profile
A Phase I/ II Trial of Pazopanib Alternating With Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Pazopanib (Primary)
- Indications Cancer metastases; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 30 Jan 2024 Planned End Date changed from 2 Jan 2024 to 2 Jan 2025.
- 30 Jan 2024 Planned primary completion date changed from 2 Jan 2024 to 2 Jan 2025.
- 29 Nov 2023 Planned End Date changed from 21 Nov 2023 to 2 Jan 2024.